Drug Profile


Alternative Names: 18-F FTPP; BFPET; BFPET (18)F-TPP

Latest Information Update: 28 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School; Massachusetts General Hospital
  • Developer FluoroPharma
  • Class Imaging agents; Organophosphorus compounds
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Coronary artery disease

Most Recent Events

  • 31 Mar 2017 Phase I development for Coronary artery disease (Diagnosis) is ongoing USA (IV)
  • 31 Mar 2017 FluoroPharma has patent protection for the composition and method of use of 18-F FCPHA and 18-F FTPP technologies
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Coronary artery disease(Diagnosis, In volunteers) in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top